PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology
暂无分享,去创建一个
V. Reuter | S. Tickoo | S. Fine | G. Iyer | H. Al-Ahmadie | B. Bochner | D. Bajorin | D. Solit | A. Gopalan | J. Rosenberg | G. Dalbagni | H. Reis | M. Teo | S. Funt | S. Sirintrapun | Rene Serrette | Ying-bei Chen | J. Posada | Vincent Lu
[1] A. Chinnaiyan,et al. Frequent PD-L1 Protein Expression and Molecular Correlates in Urinary Bladder Squamous Cell Carcinoma. , 2018, European urology.
[2] K. Higgins,et al. PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma , 2018, The American journal of surgical pathology.
[3] P. Hegde,et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial , 2018, The Lancet.
[4] A. Gown,et al. Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression , 2017, Modern Pathology.
[5] N. Socci,et al. Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis , 2017, Clinical Cancer Research.
[6] C. Drake,et al. Biomarkers for immunotherapy in bladder cancer: a moving target , 2017, Journal of Immunotherapy for Cancer.
[7] T. Powles,et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. , 2017, The Lancet. Oncology.
[8] Steven J. M. Jones,et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer , 2017, Cell.
[9] G. Freeman,et al. Differential Expression of PD‐L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications , 2017, The Journal of urology.
[10] Nicholas J. Vogelzang,et al. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study , 2017, JAMA oncology.
[11] A. Pircher,et al. PD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomy , 2017, Oncotarget.
[12] D. Schrijvers,et al. Epitope mapping of PD-L1 primary antibodies (28-8, SP142, SP263, E1L3N). , 2017 .
[13] Haiying Xu,et al. PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison , 2017, Clinical Cancer Research.
[14] A. Ravaud,et al. Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] E. Plimack,et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. , 2017, The Lancet. Oncology.
[16] T. Powles,et al. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now. , 2017, Cancer treatment reviews.
[17] S. Culine,et al. Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma , 2017, The New England journal of medicine.
[18] F. Hirsch,et al. PD‐L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD‐L1 IHC Assay Comparison Project , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[19] R. Bourgon,et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial , 2017, The Lancet.
[20] W. Weichert,et al. The Role of PD-L1 Expression and Intratumoral Lymphocytes in Response to Perioperative Chemotherapy for Urothelial Carcinoma , 2016, Bladder cancer.
[21] T. Curiel,et al. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] G. Freeman,et al. Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma , 2016, Scientific Reports.
[23] R. Bourgon,et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.
[24] R. Assi,et al. Programmed Death-Ligand 1 Expression in Muscle-Invasive Bladder Cancer Cystectomy Specimens and Lymph Node Metastasis: A Reliable Treatment Selection Biomarker? , 2016, Clinical genitourinary cancer.
[25] B. Taylor,et al. Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer , 2016, Nature Genetics.
[26] J. Taube,et al. The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder , 2016, Oncoimmunology.
[27] J. Taube,et al. Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma. , 2015, Urology.
[28] G. Freeman,et al. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[29] J. Cheville,et al. The impact of histological reclassification during pathology re-review--evidence of a Will Rogers effect in bladder cancer? , 2013, The Journal of urology.
[30] Haidong Dong,et al. PD‐L1 (B7‐H1) expression by urothelial carcinoma of the bladder and BCG‐induced granulomata , 2007, Cancer.
[31] P. Russo,et al. Cystectomy for bladder cancer: a contemporary series. , 2001, The Journal of urology.
[32] D Nicholson,et al. Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer. , 1990, Cancer research.
[33] A. Jemal,et al. Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.
[34] Jacques Ferlay,et al. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. , 2017, European urology.